Full text
Earnings transcript
Read the complete earnings call transcript.
TMO
Thermo Fisher Scientific Inc.
$491.46
-3.08
(-0.62%)
| Exchange: | NYSE |
| Market Cap: | 182.57B |
| Shares Outstanding: | 48.801M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Marc N. Casper | |||||
| Full Time Employees: | 125000 | |||||
| Address: |
| |||||
| Website: | https://www.thermofisher.com |
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company’s Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company’s Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics develops, manufactures and markets complete bloodtest systems to support the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 42,857,000 | 42,879,000 | 44,556,000 |
| Gross Profit | 17,194,000 | 17,728,000 | 16,778,000 |
| EBITDA | 11,195,000 | 11,800,000 | 11,466,000 |
| Operating Income | 7,446,000 | 7,662,000 | 8,109,000 |
| Net Income | 5,995,000 | 6,335,000 | 6,737,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 98,726,000 | 97,321,000 | 110,343,000 |
| Total Liabilities | 51,884,000 | 47,650,000 | 56,807,000 |
| Total Stockholders Equity | 46,735,000 | 49,584,000 | 53,415,000 |
| Total Debt | 36,424,000 | 32,775,000 | 39,385,000 |
| Cash and Cash Equivalents | 8,083,000 | 4,009,000 | 9,852,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 8,406,000 | 8,667,000 | 7,818,000 |
| Capital Expenditure | -1,479,000 | -1,400,000 | -1,525,000 |
| Free Cash Flow | 6,927,000 | 7,267,000 | 6,293,000 |
| Net Income | 5,995,000 | 6,338,000 | 6,721,000 |
| Net Change in Cash | -440,000 | -4,057,000 | 5,839,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 57,160,533.111 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 58,734,511.909 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 58,183,000 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 15,603,403.084 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 16,033,060.127 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 15,882,511.100 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 13,918,900.356 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 14,419,842.878 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 14,244,315.447 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 11,023,363.477 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 11,326,904.040 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 11,220,545.406 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 37.780 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 38.250 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 36.920 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 7 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 2 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- Robust Financial Performance: TMO demonstrates strong revenue and net income figures in recent income statements, supported by consistent growth in operating cash flow and free cash flow as per cash flow statements. This indicates a solid operational foundation and ability to generate sustainable cash for reinvestment or shareholder returns.
- Market Leadership in Sector: As part of the healthcare equipment and services industry within the broader healthcare sector, TMO benefits from a strong market position, reflected in its substantial market capitalization and consistent performance metrics (perf1y, perf5y) that often outperform industry averages (industry_perf1y, industry_perf5y).
- High Profitability Metrics: Key metrics such as gross profit margin (grossProfitMarginTTM) and net profit margin (netProfitMarginTTM) are indicative of efficient cost management and pricing power, positioning TMO favorably against competitors in the sector.
- Strong Balance Sheet: The balance sheet data highlights a healthy level of cash and cash equivalents alongside manageable total liabilities relative to total assets, suggesting financial stability and resilience (totalCurrentAssets, totalLiabilities, totalStockholdersEquity).
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates TMO intrinsic value between $279.19 – $473.97 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about TMO valuation
Is Thermo Fisher Scientific Inc. (TMO) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Thermo Fisher Scientific Inc. (TMO) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is TMO a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether TMO trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is TMO’s P/E ratio?
You can see TMO’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for TMO?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is TMO a good long-term investment?
Whether TMO fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
TMO
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.62
Trading Metrics:
| Open: | 486.94 | Previous Close: | 494.54 | |
| Day Low: | 485.11 | Day High: | 506.82 | |
| Year Low: | 385.46 | Year High: | 643.99 | |
| Price Avg 50: | 521.61 | Price Avg 200: | 518.47 | |
| Volume: | 1.696M | Average Volume: | 2.169M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeTMO full analysis
Hey everyone, welcome back to the channel! Today, we’re diving deep into Thermo Fisher Scientific, ticker TMO, a heavyweight in the life sciences and diagnostics space. If you’re looking to understand whether this stock deserves a spot in your portfolio, stick around because I’m breaking down everything from financials to recent performance, valuation, and more. Let’s get started! So, what’s the big picture with Thermo Fisher Scientific? This is a company that’s been around since 1956, headquartered in Waltham, Massachusetts,…
